Article
AREDS2 study to test home monitoring
The National Eye Institute (NEI) has launched an ancillary study to the ongoing Age-Related Eye Disease Study 2, which has the aim of determining whether oral supplementation of lutein/zeaxanthin and omega-3 fatty acids can further slow the progression of vision loss from age-related macular degeneration.
St. Louis-The National Eye Institute (NEI) has launched an ancillary study to the ongoing Age-Related Eye Disease Study 2 (AREDS2), which has the aim of determining whether oral supplementation of lutein/zeaxanthin and omega-3 fatty acids can further slow the progression of vision loss from age-related macular degeneration (AMD).
The objective of the ancillary study is to determine whether home monitoring using a proprietary monitor (ForeseeHome AMD Monitor, Notal Vision) will lead to earlier detection of wet AMD when compared with standard care and will result in better visual acuity following therapy at 1 year.
The proprietary monitor is the first ophthalmic device designed to provide ongoing monitoring of patients with AMD between visits to an eye-care professional. Patients complete a brief exam on the monitor in their own homes, and data are transmitted to the company’s monitoring center.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
